More than 390 million human dengue virus (DENV) infections occur each year, worldwide. Dengvaxia, a live-virus tetravalent vaccine from Sanofi Pasteur, was recently approved for clinical use, although performance against the four DENV serotypes is highly variable. Other vaccines in advanced testing also demonstrate variability efficacy. In this review, we outline benefits and challenges of deve...